Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,927,270 papers from all fields of science
Search
Sign In
Create Free Account
chlorodihydroxypyridine
Known as:
5-Chloro-2,4-dihydroxypyridinediol
, CDHP
, GIMERACIL
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Narrower (1)
gimeracil
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma.
Huiping Zhu
,
X. Ge
,
+4 authors
Min Yang
Oncology Letters
2018
Corpus ID: 58599843
Concurrent chemoradiotherapy (CCRT) is an effective first-line treatment for esophageal squamous cell carcinoma (ESCC). The…
Expand
2014
2014
Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer.
Cuicui Meng
,
Zhonghua Lu
,
+5 authors
Zhibin Luo
International Journal of Clinical and…
2014
Corpus ID: 11450614
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has been reported to have antitumor effects. In some tumor models, the…
Expand
2013
2013
S‐1 induced a durable response in metastatic extramammary Paget's disease
Y. Mikoshiba
,
H. Uhara
,
H. Kubo
,
R. Okuyama
Journal of dermatology (Print)
2013
Corpus ID: 13717055
Dear Editor, We report the case of an 81-year-old man with a 3-year history of extramammary Paget’s disease (EMPD) in his scrotum…
Expand
2013
2013
Five-Year Survival of Alpha-Fetoprotein-Producing Gastric Cancer with Synchronous Liver Metastasis: A Case Report
K. Koneri
,
Y. Hirono
,
+7 authors
A. Yamaguchi
Journal of Gastric Cancer
2013
Corpus ID: 400798
Alpha-fetoprotein-Producing gastric cancer is associated with poor prognosis because of frequent liver and lymph node metastasis…
Expand
Review
2010
Review
2010
S-1 induces meibomian gland dysfunction.
Y. Matsumoto
,
M. Doğru
,
+4 authors
K. Tsubota
Ophthalmology (Rochester, Minn.)
2010
Corpus ID: 30141193
2009
2009
Consumer-Driven Health Plans: Impact on Utilization and Expenditures for Chronic Disease Sufferers
K. Nair
,
Jinhee Park
,
P. Wolfe
,
J. Saseen
,
R. Allen
,
R. Ganguly
Journal of Occupational and Environmental…
2009
Corpus ID: 25286062
Objectives: The impact of consumer-driven health plans (CDHPs) on utilization and expenditures for members with chronic diseases…
Expand
2009
2009
An Identity-Based Proxy Signature from Bilinear Pairings
Huifang Ji
,
Wenbao Han
,
Long Zhao
,
Yongjuan Wang
WASE International Conference on Information…
2009
Corpus ID: 17577800
Currently, ID-based PKC has attracted much attention and got manyachievements. Proxy signature allows an original signer to…
Expand
2006
2006
Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Y. Nakayama
,
Kentaro Matsumoto
,
+8 authors
H. Itoh
Anticancer Research
2006
Corpus ID: 37721803
BACKGROUND The determination of dihydropyrimidine dehydrogenase (DPD) deficiency is important in avoiding severe 5-fluorouracil…
Expand
2006
2006
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1
Y. Tsuruoka
,
T. Kamano
,
+5 authors
T. Shirasaka
Anti-Cancer Drugs
2006
Corpus ID: 44769359
The effect of gastrectomy on pharmacokinetics after S-1 administration was investigated in a total of 12 cases – nine in which…
Expand
2001
2001
Chronic delusional hallucinatory psychosis in early-onset Parkinson's disease: drug-induced complication or sign of an idiopathic psychiatric illness?
A. Cannas
,
A. Spissu
,
+7 authors
Marcello Giagheddu
Neurological Sciences
2001
Corpus ID: 7298821
Abstract Chronic delusional psychosis with hallucinations (CDHP) is commonly assumed to complicate the later stages of Parkinson…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE